Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis
Conditions
Interventions
TVB-009
Prolia®
Locations
78
United States
Teva Site 103
Phoenix, Arizona, United States
Teva Site 119
Tucson, Arizona, United States
Teva Site 118
San Diego, California, United States
Teva Site 107
New London, Connecticut, United States
Teva Site 115
Coral Gables, Florida, United States
Teva Site 114
Edgewater, Florida, United States
Start Date
March 22, 2021
Primary Completion Date
December 31, 2022
Completion Date
June 19, 2023
Last Updated
April 18, 2024
NCT06558188
NCT05575167
NCT05228262
NCT03232476
NCT04964388
NCT00389740
Lead Sponsor
Teva Pharmaceuticals USA
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions